Expression patterns across tissues at all developmental stages
Our IHC services are led by the scientists behind the development of low‑HER2 and PD‑L1 CDx assays, delivering precise and actionable insights for biomarker development, therapeutic target validation, and prevalence studies from preclinical research through CDx development.
Decades of experience developing, validating and applying IHC assays throughout every stage of development for leading biotech and pharma clients.
A technology agnostic approach to enable an unbiased selection of the most suitable platforms.
Global standardization and harmonization of IHC assays including global clinical trial testing and our Biomarker Academy™ training programs with post-approval services.
Access to the world’s largest commercial biorepository to build optimal study cohorts.
We use a technology-agnostic approach so you can choose the right technology for your project. Our expert scientists work with you consultatively to make sure your study is designed to achieve optimal outcomes.
Our experts have designed an industry-leading assay validation approach that starts with careful IHC assay development and optimization. We do more than simply demonstrate that an assay can detect a target in various conditions, we:
Helping you understand your target biomarkers at every stage of research and clinical development using any leading technology platform.
Clarity Before You Start
We align on study goals, timelines, and biological context, including mechanism of action, target biomarkers, and intended use. Our team helps define the right tissues, indications, and controls, and identifies optimal antibodies to support confident downstream analysis.
Validated for Performance and Reproducibility
We optimize pretreatment conditions, confirm assay specificity, and evaluate sensitivity, range, and linearity. Scoring approaches are developed and validated to ensure robust, reproducible results aligned with applicable GCLP expectations.
Consistent Results at Research or Clinical Scale
We perform IHC testing on research or clinical samples using validated methods and scoring criteria. Expression patterns, tumor surveys, and cutoff thresholds are generated to support biomarker prevalence assessment and patient stratification.
Integrated labs maintain chain-of-custody and accelerate EU trial startup.
Insights You Can Act On
Full-service pathology review and customized reporting translate staining data into meaningful biological insight. Outputs are delivered in study- and submission-ready formats, with support for IND-enabling programs and Prototype CDx planning.
